4.47
-2.61%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hangzhou Jiuyuan Genetic Biopharmaceutical Co
Its shares trade on HKEX under the ticker 2566.HK. It has been listed since 28 November 2024. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.31bn and net income of CN¥138.4m. At that date it held total assets of CN¥2.12bn and shareholders' equity of CN¥1.65bn.
Hangzhou Jiuyuan Gene Engineering Co Ltd is a CN-based company operating in industry. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2024-11-28. Hangzhou Jiuyuan Gene Engineering Co Ltd is a China-based company mainly engaged in the research and development of genetic drugs. The firm's main business is the research and development, production, and sales of biopharmaceuticals and related medical devices. The firm's main products include bone repair materials, generic enoxaparin sodium, human granulocyte stimulating factor, and injectable interleukin. The firm's products are mainly used for the treatment of orthopedic, tumor, and hematological diseases. The firm mainly conducts its business in domestic and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 28 Nov 2024
- Website
- china-gene.com ↗
Leadership
Pay as last reported
- Mr. Hang FuExecutive Chairman of the Board, General Manager, since 2000
- Mr. Wei ZhouDeputy General Manager, General Manager - Pharmacy services, Executive Director, since 2014
- Mr. Hui LiDeputy General Manager, Chief Manager - Manufacturing Center
- Mr. Handong SunDeputy General Manager, Chief Manager - Research and Development Center
- Ms. Yanmei YangFinancial Controller
- Ms. Wing Nga HoJoint Company Secretary
- Ms. Xiu HuangSecretary to the Board, Joint Company Secretary
- Mr. Albert CruellaNon-Executive Director
- Mr. Junjie FeiNon-Executive Director
- Ms. Honglan MaNon-Executive Director
- Mr. Shihang WuNon-Executive Director
- Ms. Mei Yi HoIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd develops bone repair materials for orthopedic treatments.
- Hangzhou Jiuyuan Gene Engineering Co Ltd produces generic enoxaparin sodium for anticoagulant therapy.
- Hangzhou Jiuyuan Gene Engineering Co Ltd offers human granulocyte stimulating factor for cancer treatment.
Weaknesses
- Hangzhou Jiuyuan Gene Engineering Co Ltd focuses on domestic and overseas markets without specific regional expansion plans.
- Hangzhou Jiuyuan Gene Engineering Co Ltd has no mention of R&D investment in the provided facts.
- Hangzhou Jiuyuan Gene Engineering Co Ltd does not specify product pricing strategies.
Opportunities
- Hangzhou Jiuyuan Gene Engineering Co Ltd can expand into the global biopharmaceutical market for orthopedic treatments.
- Hangzhou Jiuyuan Gene Engineering Co Ltd can leverage its injectable interleukin for hematological disease treatments.
- Hangzhou Jiuyuan Gene Engineering Co Ltd can target the growing demand for biopharmaceuticals in China.
Threats
- Hangzhou Jiuyuan Gene Engineering Co Ltd faces competition from established biopharmaceutical companies in China.
- Hangzhou Jiuyuan Gene Engineering Co Ltd must comply with evolving regulatory standards in the biopharmaceutical industry.
- Hangzhou Jiuyuan Gene Engineering Co Ltd has no mention of international market entry strategies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.